Association of ITPA polymorphism with outcomes of peginterferon-? plus ribavirin combination therapy.
Ontology highlight
ABSTRACT: AIM:To analyzed the association between inosine triphosphatase (ITPA) (rs1127354) genotypes and sustained virological response (SVR) rates in peginterferon (Peg-IFN)? + ribavirin (RBV) treatment. METHODS:Patients who underwent Peg-IFN? + RBV combination therapy were enrolled (n = 120) and they had no history of other IFN-based treatments. Variation in hemoglobin levels during therapy, cumulative reduction of RBV dose, frequency of treatment withdrawal, and SVR rates were investigated in each ITPA genotype. RESULTS:In patients with ITPA CC genotype, hemoglobin decline was significantly greater and the percentage of patients in whom total RBV dose was < 60% of standard and/or treatment was withdrawn was significantly higher compared with CA/AA genotype. However, SVR rates were equivalent between CC and CA/AA genotypes, and within a subset of patients with Interleukin 28B (IL28B) (rs8099917) TT genotype, SVR rates tended to be higher in patients with ITPA CC genotype, although the difference was not significant. CONCLUSION:ITPA CC genotype was a disadvantageous factor for Peg-IFN? + RBV treatment in relation to completion rates and RBV dose. However, CC genotype was not inferior to CA/AA genotype for SVR rates. When full-length treatment is accomplished, it is plausible that more SVR is achieved in patients with ITPA CC variant, especially in a background of IL28B TT genotype.
SUBMITTER: Fujino T
PROVIDER: S-EPMC3729868 | biostudies-literature | 2013 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA